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YONEMORI Et al. growth factor receptor α (PDGFRα). 4 In a randomized phase 1b/2 study, olaratumab (15 mg/kg) plus doxorubicin (75 mg/m 2 ) met the predefined primary endpoint for progression-free survival (PFS) and significantly improved overall survival (OS) by 11.8 months vs doxorubicin alone in patients with advanced STS. 5 The safety profile of this regimen was found to be acceptable and the benefit-risk profile positive. Olaratumab has since received FDA accelerated approval for use with doxorubicin for treating advanced STS and conditional approval in the European Union, Canada and South Korea for use with doxorubicin for treating advanced STS.
To date, there is limited information available on the efficacy and safety of olaratumab in Japanese patients. In a phase 1 doseescalation study of Japanese patients with advanced/refractory solid malignancies, olaratumab monotherapy was found to have an acceptable safety profile and was well tolerated. 6 The safety of olaratumab plus doxorubicin in Japanese patients with STS has not been reported in the published literature.
The primary objective of this phase 1 study was to evaluate the safety and tolerability of olaratumab plus doxorubicin in Japanese patients with advanced STS. The main secondary objective was to evaluate the pharmacokinetic (PK) profile of olaratumab following a 20 mg/kg loading dose.
| MATERIAL S AND ME THODS

| Study design
This open-label, nonrandomized, multicenter phase 1 study evaluated olaratumab plus doxorubicin in Japanese patients with advanced STS (ClinicalTrials.gov Identifier: NCT02377752). This study also included a second part that evaluated olaratumab monotherapy;
results for the second part of the study are not reported here.
All patients provided written informed consent, and the protocol and informed consent form were approved by ethics review boards at each site. The study was conducted in accordance with the
Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines and the
International Conference on Harmonisation Good Clinical Practices
Guideline (E6).
| Study population
Key inclusion criteria were: age ≥20 years; histologically/cytologically confirmed advanced or metastatic solid tumor, in particular Key exclusion criteria were previous treatment with anthracyclines and previous radiotherapy to the mediastinal/pericardial area.
| Study treatment
There were 3 treatment cohorts (minimum 6 patients each No premedication, including steroids or diphenhydramine, was mandated prior to treatment with olaratumab. Supportive care with granulocyte colony stimulating factor (G-CSF) was permitted at the investigator's discretion; however, primary prophylaxis with G-CSF was not allowed.
Dexrazoxane, a cardioprotectant for anthracycline-induced cardiotoxicity, is not approved in Japan and was, therefore, not used in the study.
| Safety assessments
Treatment-emergent adverse events (TEAE) were summarized using were not to be considered a DLT. Echocardiogram scans were performed prior to the start of Cycles 5 and 7, and at the follow-up visit.
| Pharmacokinetics/immunogenicity assessments
Blood samples were collected throughout Cycles 1 and 3 to determine serum olaratumab concentrations using a validated ELISA, carried out by ICON Development Solutions (Whitesboro, NY). The lower limit of quantitation was 1 μg/mL and the upper limit of quantification was 100 μg/mL. Olaratumab PK parameters were calculated using a standard noncompartmental method of analysis. Blood samples were analyzed for the presence or absence of antidrug antibodies (ADA) using a validated ELISA, carried out by Pharmaceutical Product Development (Richmond, VA, USA). Samples identified as being ADA-positive were further evaluated for the presence of neutralizing antibodies.
| Antitumor activity assessments
Patients were assessed by computed tomography scan and/or MRI for tumor measurement according to the Response Evaluation Criteria in Solid Tumors (Version 1.1). 11 The objective response rate (ORR), the disease control rate (DCR) and PFS were determined.
| Statistical analysis
The sample size was determined by the study design, rather than a statistical power calculation. Six patients in each cohort were required to assess DLT. 
| RE SULTS
| Patient disposition and baseline characteristics
In total, 19 enrolled patients received the study drugs and were included in the safety and efficacy analyses ( Figure 1 ). All patients had STS, with leiomyosarcoma and liposarcoma being the most common subtypes. One patient in Cohort 1 was replaced for DLT analysis because of a Grade 4 IRR in Cycle 1. The majority of patients discontinued study treatment because of PD.
Baseline characteristics and extent of exposure are summarized in Tables 1 and 2 , respectively.
| Safety and tolerability
There were no DLT in Cohorts 1 or 3. One patient in Cohort 2 ex- due to further deterioration of EF to 30%. This event was deemed to be a doxorubicin-induced cardiotoxicity.
TA B L E 1 Baseline characteristics
| Pharmacokinetics
Olaratumab PK parameters are summarized in Table 4 .
Serum olaratumab concentration data were available for 18 patients ( Figure 2 ). The number of patients achieving olaratumab plasma concentration above the target trough level (>66 μg/mL)
in Cycle 1 was 3/8 (37.5%) for Cohorts 1 and 2 combined, and 5/6
(83.3%) for Cohort 3.
| Antitumor activity
A partial response was confirmed in 2 patients each in Cohorts 2 and 3 ( Figure 3 ), giving an ORR of 33.3% in each of these cohorts (Table 5) . No patient in Cohort 1 had a PR. The DCR were 42.9%, 83.3% and 66.7% in Cohorts 1, 2 and 3, respectively (Table 5) . 
| Immunogenicity
Anti-drug antibodies were not detected in any patients, including the patient who experienced an IRR.
| D ISCUSS I ON
This is the first report on olaratumab plus doxorubicin in Japanese patients with advanced STS. Key findings from the study include TA B L E 3 Summary of Grade 3/4 treatment-emergent averse events (regardless of causality) occurring in ≥1 patient in any cohort that this combination had an acceptable safety profile, and that an olaratumab 20 mg/kg loading dose in Cycle 1 led to early achievement of steady-state serum concentrations above the target trough level while preserving the safety profile of olaratumab observed with 15 mg/kg dose.
The safety and tolerability findings from this study are consistent with those from the phase 1b/2 study of olaratumab plus doxorubicin in, predominantly, Caucasian patients with advanced STS. 5 Few patients discontinued due to TEAE and only 1 patient 
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